Drug Intervention in Chronic Fatigue Syndrome (KTS-1-2008)

This study has been completed.

Sponsor:

ClinicalTrials.gov Identifier:

NCT00848692

First Posted: February 20, 2009

Last Update Posted: June 2, 2011

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

Information provided by:

Haukeland University Hospital

Purpose

Based on pilot patient observations,the investigators anticipate that chronic fatigue syndrome (CFS) patients may benefit from B-cell depletion therapy.

The hypothesis is that at least a subset of CFS patients have an activated immune system involving B-lymphocytes, and that B-cell depletion may alleviate symptoms.

Condition	Intervention	Phase
Chronic Fatigue Syndrome	Drug: Rituximab Drug: Saline (NaCl 0,9 %) (placebo)	Phase 2 Phase 3


Study Type:	Interventional
Study Design:	Allocation: Randomized Intervention Model: Parallel Assignment Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) Primary Purpose: Treatment
Official Title:	B-cell Depletion Using the Monoclonal Anti-CD20 Antibody Rituximab in Chronic Fatigue Syndrome. A Double-blind, Placebo-controlled Study.

Resource links provided by NLM:

MedlinePlus related topics: Chronic Fatigue Syndrome Fatigue

Drug Information available for: Rituximab

U.S. FDA Resources

Further study details as provided by Haukeland University Hospital:

Primary Outcome Measures:

Symptom alleviation, as compared to baseline, measured by standardized self-reports and quality of life schemes. [ Time Frame: 3 months after intervention ]

Secondary Outcome Measures:

Symptom alleviation, as compared to baseline, measured by standardized self-reports and quality of life schemes [ Time Frame: 2, 4, 6, 8, 10, 12 months after intervention ]


Estimated Enrollment:	30
Study Start Date:	June 2008
Study Completion Date:	June 2010
Primary Completion Date:	June 2010 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
Experimental: 1 Rituximab	Drug: Rituximab Two infusions of Rituximab 500 mg/m2 (max 1000 mg) given two weeks apart
Placebo Comparator: 2 Placebo (saline)	Drug: Saline (NaCl 0,9 %) (placebo) Two infusions of saline (NaCl 0,9 %) given two weeks apart

Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:	18 Years to 60 Years (Adult)
Sexes Eligible for Study:	All
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

verified chronic fatigue syndrome (CDC-criteria)
age >18 and <60 years
informed consent

Exclusion Criteria:

pregnancy or lactation
previous malignant disease except basal cell carcinoma of skin and cervical carcinoma in situ
previous long-term use of immunosuppressive drugs
previous exposure to rituximab
endogenous depression
multi-allergy with risk of serious drug reaction
reduced renal function (creatinin > 1.2 x UNL)
reduced liver function (bilirubin or transaminases > 1.5 x UNL)
known HIV infection
signs of active viral infection by pretreatment investigations

Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00848692

Locations


Norway
Department of Oncology and Medical Physics, Haukeland University Hospital
Bergen, Norway, N-5021

Sponsors and Collaborators

Haukeland University Hospital

Investigators


Principal Investigator:	Olav Mella, MD, PhD	Department of Oncology and Medical Physics, Haukeland University Hospital

More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Fluge Ø, Bruland O, Risa K, Storstein A, Kristoffersen EK, Sapkota D, Næss H, Dahl O, Nyland H, Mella O. Benefit from B-lymphocyte depletion using the anti-CD20 antibody rituximab in chronic fatigue syndrome. A double-blind and placebo-controlled study. PLoS One. 2011;6(10):e26358. doi: 10.1371/journal.pone.0026358. Epub 2011 Oct 19.


Responsible Party:	Olav Mella, Professor, Department Director, Department of Oncology and Medical Physics, Haukeland University Hospital
ClinicalTrials.gov Identifier:	NCT00848692 History of Changes
Other Study ID Numbers:	18257 EudraCT: 2007-007973-22
First Submitted:	February 19, 2009
First Posted:	February 20, 2009
Last Update Posted:	June 2, 2011
Last Verified:	June 2011

Keywords provided by Haukeland University Hospital:


Chronic Fatigue Syndrome CFS Myalgic Encephalomyelitis	Rituximab B-lymphocyte depletion B-cell depletion

Additional relevant MeSH terms:


Syndrome Fatigue Fatigue Syndrome, Chronic Disease Pathologic Processes Signs and Symptoms Virus Diseases Muscular Diseases Musculoskeletal Diseases	Encephalomyelitis Central Nervous System Diseases Nervous System Diseases Neuromuscular Diseases Rituximab Antineoplastic Agents Immunologic Factors Physiological Effects of Drugs Antirheumatic Agents

To Top